Aileron Therapeutics Presents New Data on Stapled Peptide Oncology Program at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics
11/7/2012 9:20:19 AM
CAMBRIDGE, Mass. & DUBLIN--(BUSINESS WIRE)--Aileron Therapeutics, Inc. and its collaborator Roche today announced new results of a preclinical study of its Stapled Peptide oncology drug candidate ATSP-7041, which exhibited robust efficacy in MDM2 and MDMX xenograft cancer models. The study represents an important step towards establishing ATSP-7041 as the first highly potent and specific dual inhibitor of MDM2 and MDMX for p53-dependent cancers. ATSP-7041 was developed as part of Aileron’s collaboration with Roche to discover, develop and commercialize Staple Peptide drugs. The data were presented today at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (abstract number 226).